Could Intravenous Immunoglobulin Collected ...
Type de document :
Article dans une revue scientifique
DOI :
PMID :
URL permanente :
Titre :
Could Intravenous Immunoglobulin Collected from Recovered Coronavirus Patients Protect against COVID-19 and Strengthen the Immune System of New Patients?
Auteur(s) :
Titre de la revue :
International journal of molecular sciences
Nom court de la revue :
Int J Mol Sci
Numéro :
21
Date de publication :
2020-03-25
ISSN :
1422-0067
Mot(s)-clé(s) en anglais :
Animals
Betacoronavirus
COVID-19
Coronavirus Infections
Humans
Immune System
Immunization, Passive
Immunoglobulins, Intravenous
Mice
Pandemics
Periodicals as Topic
Pneumonia, Viral
SARS-CoV-2
IVIg
coronavirus
immunotherapy
nCoV-2019
virus
Betacoronavirus
COVID-19
Coronavirus Infections
Humans
Immune System
Immunization, Passive
Immunoglobulins, Intravenous
Mice
Pandemics
Periodicals as Topic
Pneumonia, Viral
SARS-CoV-2
IVIg
coronavirus
immunotherapy
nCoV-2019
virus
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains ...
Lire la suite >The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains that cross the species barrier and infect humans. At the present, there is no single specific vaccine or efficient antiviral therapy against COVID-19. Recently, we showed that intravenous immunoglobulin (IVIg) treatment reduces inflammation of intestinal epithelial cells and eliminates overgrowth of the opportunistic human fungal pathogen in the murine gut. Immunotherapy with IVIg could be employed to neutralize COVID-19. However, the efficacy of IVIg would be better if the immune IgG antibodies were collected from patients who have recovered from COVID-19 in the same city, or the surrounding area, in order to increase the chance of neutralizing the virus. These immune IgG antibodies will be specific against COVID-19 by boosting the immune response in newly infected patients. Different procedures may be used to remove or inactivate any possible pathogens from the plasma of recovered coronavirus patient derived immune IgG, including solvent/detergent, 60 °C heat-treatment, and nanofiltration. Overall, immunotherapy with immune IgG antibodies combined with antiviral drugs may be an alternative treatment against COVID-19 until stronger options such as vaccines are available.Lire moins >
Lire la suite >The emergence of the novel coronavirus in Wuhan, China, which causes severe respiratory tract infections in humans (COVID-19), has become a global health concern. Most coronaviruses infect animals but can evolve into strains that cross the species barrier and infect humans. At the present, there is no single specific vaccine or efficient antiviral therapy against COVID-19. Recently, we showed that intravenous immunoglobulin (IVIg) treatment reduces inflammation of intestinal epithelial cells and eliminates overgrowth of the opportunistic human fungal pathogen in the murine gut. Immunotherapy with IVIg could be employed to neutralize COVID-19. However, the efficacy of IVIg would be better if the immune IgG antibodies were collected from patients who have recovered from COVID-19 in the same city, or the surrounding area, in order to increase the chance of neutralizing the virus. These immune IgG antibodies will be specific against COVID-19 by boosting the immune response in newly infected patients. Different procedures may be used to remove or inactivate any possible pathogens from the plasma of recovered coronavirus patient derived immune IgG, including solvent/detergent, 60 °C heat-treatment, and nanofiltration. Overall, immunotherapy with immune IgG antibodies combined with antiviral drugs may be an alternative treatment against COVID-19 until stronger options such as vaccines are available.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CNRS
CNRS
Équipe(s) de recherche :
Glycobiology in fungal Pathogenesis and Clinical Applications
Date de dépôt :
2021-07-05T08:53:50Z
2021-07-07T08:28:05Z
2021-07-07T08:28:05Z
Fichiers
- ijms-21-02272-v2.pdf
- Version éditeur
- Accès libre
- Accéder au document